Resistant starch type-2 enriched cookies modulate uremic toxins and inflammation in hemodialysis patients: a randomized, double-blind, crossover and placebo-controlled trial

被引:5
|
作者
Esgalhado, Marta [1 ]
Kemp, Julie Ann [1 ]
Paiva, Bruna R. de [1 ]
Brito, Jessyca Sousa [2 ]
Cardozo, Ludmila F. M. F. [1 ]
Azevedo, Renata [1 ]
Cunha, Diana Barbosa [3 ]
Nakao, Lia S. [4 ]
Mafra, Denise [1 ,2 ]
机构
[1] Fluminense Fed Univ, Post Grad Program Cardiovasc Sci, Niteroi, RJ, Brazil
[2] Fluminense Fed Univ, Post Grad Program Med Sci, Niteroi, RJ, Brazil
[3] Univ Estado Rio De Janeiro, Dept Epidemiol, Inst Social Med, Rio De Janeiro, Brazil
[4] Fed Univ Parana UFPR, Basic Pathol Dept, Curitiba, PR, Brazil
关键词
CHRONIC KIDNEY-DISEASE; P-CRESYL SULFATE; NF-KAPPA-B; OXIDATIVE STRESS; GUT MICROBIOTA; INDOXYL SULFATE; FIBER SUPPLEMENTATION; SYSTEMIC INFLAMMATION; PROTECTIVE ROLE; DIETARY FIBER;
D O I
10.1039/c9fo02939g
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: The aim of this study was to evaluate the effect of resistant starch (RS) enriched cookies supplementation on mRNA expression of nuclear transcription factors (nuclear erythroid 2-related factor, Nrf2; nuclear factor kappa-B, NF-kappa B), involved with inflammation and on uremic toxins levels produced by the gut microbiota in hemodialysis (HD) patients. Methods: A randomized, double-blind, placebo-controlled crossover study with 26 HD patients was conducted. The patients were assigned to either resistant starch enriched cookies (16 g of RS per day) or placebo cookies supplementation during the first four weeks. After the washout period, patients were supplemented again, in the form of a crossover, for another 4 weeks. Nrf2, NF-kappa B, and antioxidant enzymes mRNA expression were measured by rt-PCR and protein expression by western blotting assay from isolated peripheral blood mononuclear cells (PBMC). Oxidative stress and inflammatory biomarkers, as well as uremic toxins, were evaluated. Intention-to-treat analysis was performed, using the proc mixed procedure in SAS. Results: In RS group, post-treatment mean mRNA Nrf2 expression was market increased from baseline values, associated with a high expression of NQO1 protein. Besides, IS plasma levels were reduced in the RS group. No significant difference was observed in the placebo group. Conclusion: Our results suggested that resistant starch enriched cookies may be a good nutritional strategy to reduce indoxyl sulfate levels derived from the gut microbiota and also attenuate the inflammation in hemodialysis patients.
引用
收藏
页码:2617 / 2625
页数:9
相关论文
共 50 条
  • [1] The Impact of Enriched Resistant Starch Type-2 Cookies on the Gut Microbiome in Hemodialysis Patients: A Randomized Controlled Trial
    Kemp, Julie Ann
    de Paiva, Bruna Regis
    dos Santos, Henrique Fragoso
    de Jesus, Hugo Emiliano
    Craven, Hannah
    Ijaz, Umer Z.
    Borges, Natalia Alvarenga
    Shiels, Paul G.
    Mafra, Denise
    MOLECULAR NUTRITION & FOOD RESEARCH, 2021, 65 (19)
  • [2] The impact of synbiotics on the uremic toxins, inflammation, and gut microbiome of CKD patients-randomized, double-blind, placebo-controlled trial
    Mitrovic, Milos
    Dimkovic, Nada
    Popovic, Verica Stankovic
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I278 - I278
  • [3] The impact of synbiotics on the uremic toxins, inflammation, and gut microbiome of CKD patients-randomized, double-blind, placebo-controlled trial
    Mitrovic, Milos
    Dimkovic, Nada
    Popovic, Verica Stankovic
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [4] EFFECT OF SENNA ON REDUCTION OF UREMIC PRURITUS IN HEMODIALYSIS PATIENTS: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL
    Fallahzadeh, Mohammad Kazem
    Faridi, Pouya
    Sarvestani, Arian Kamali
    Sagheb, Mohammad Mahdi
    Blondin, Joan
    Mohagheghzadeh, Abdolali
    Roozbeh, Jamshid
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2015, 65 (04) : A33 - A33
  • [5] Randomized, double-blind, placebo-controlled crossover trial of Famotidine in patients with functional dyspepsia
    Kato, Mototsugu
    Yoshida, Takeshi
    Hata, Tamotsu
    Ono, Yuji
    Ono, Shouko
    Nakagawa, Manabu
    Nakagawa, Souichi
    Shimizu, Yuichi
    Asaka, Masahiro
    GASTROENTEROLOGY, 2006, 130 (04) : A158 - A158
  • [6] Randomized, double-blind, placebo-controlled crossover trial of famotidine in patients with functional dyspepsia
    Kato, M
    Watanabe, M
    Konishi, S
    Kudo, M
    Konno, J
    Meguro, T
    Kitamori, S
    Nakagawa, S
    Shimizu, Y
    Takeda, H
    Asaka, M
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 : 27 - 31
  • [7] RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSSOVER TRIAL OF PIRENZEPINE IN PATIENTS WITH GASTROESOPHAGEAL REFLUX
    SATO, TL
    WU, WC
    CASTELL, DO
    DIGESTIVE DISEASES AND SCIENCES, 1992, 37 (02) : 297 - 302
  • [8] NALBUPIHNE ER TABLETS IN HEMODIALYSIS PATIENTS WITH SEVERE UREMIC PRURITUS: MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Kumar, Jayant
    Crawford, Paul
    Mathur, Vandana
    Sciascia, Thomas
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2016, 67 (05) : A65 - A65
  • [9] A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients
    Cheng, Steven C.
    Young, Daniel O.
    Huang, Yihung
    Delmez, James A.
    Coyne, Daniel W.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 3 (04): : 1131 - 1138
  • [10] Mesna for treatment of hyperhomocysteinemia in hemodialysis patients: A placebo-controlled, double-blind, randomized trial
    Urquhart, Bradley L.
    Freeman, David J.
    Cutler, Murray J.
    Mainra, Rahul
    Spence, J. David
    House, Andrew A.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 3 (04): : 1041 - 1047